menu
    • menu
    [{"orgOrder":0,"company":"Eli Lilly","sponsor":"Journey Medical Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Glycopyrronium Tosylate","moa":"M3 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Wipes","sponsorNew":"Eli Lilly \/ Journey Medical Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Journey Medical Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Maruho","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Glycopyrronium Tosylate","moa":"M3 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Wipes","sponsorNew":"Eli Lilly \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Maruho"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Maruho","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Glycopyrronium Tosylate","moa":"M3 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Wipes","sponsorNew":"Journey Medical Corporation \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Maruho"}]

    Find Clinical Drug Pipeline Developments & Deals for Glycopyrronium Tosylate

    Menu

    Glycopyrronium Tosylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Eli Lilly

    U.S.A arrow
    Cophex
    Not Confirmed

    Eli Lilly

    U.S.A arrow
    Cophex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Glycopyrronium Tosylate

    Therapeutic Area : Dermatology

    Study Phase : Approved FDF

    Sponsor : Maruho

    Deal Size : $7.5 million

    Deal Type : Agreement

    DEALS_DEV arrow-down

    QBREXZA® (Rapifort® Wipes 2.5%) Receives Manufacturing and Marketing Approval in Japan Triggering $2.5 Milli...

    Details : Journey Medical acquired global rights to QBREXZA® from Dermira in 2021. QBREXZA is a topical product approved by the U.S. Food and Drug Administration for treatment of primary axillary hyperhidrosis in adult and pediatric populations.

    Product Name : Qbrexza

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    November 02, 2022

    Lead Product(s) : Glycopyrronium Tosylate

    Therapeutic Area : Dermatology

    Highest Development Status : Approved FDF

    Sponsor : Maruho

    Deal Size : $7.5 million

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Journey Medical Corporation

    U.S.A arrow
    Cophex
    Not Confirmed

    Journey Medical Corporation

    U.S.A arrow
    Cophex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Glycopyrronium Tosylate

    Therapeutic Area : Dermatology

    Study Phase : Approved FDF

    Sponsor : Maruho

    Deal Size : $10.0 million

    Deal Type : Agreement

    DEALS_DEV arrow-down

    QBREXZA® (Rapifort® Wipes 2.5%) Receives Manufacturing and Marketing Approval in Japan Triggering $2.5 Milli...

    Details : QBREXZA (Rapifort® Wipes 2.5%), is a topical product approved by the U.S. Food and Drug Administration for treatment of primary axillary hyperhidrosis in adult and pediatric populations (ages nine-years and older) and is self-administered by patients.

    Product Name : Rapifort Wipes

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    November 02, 2022

    Lead Product(s) : Glycopyrronium Tosylate

    Therapeutic Area : Dermatology

    Highest Development Status : Approved FDF

    Sponsor : Maruho

    Deal Size : $10.0 million

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Eli Lilly

    U.S.A arrow
    World Vaccine Conference
    Not Confirmed

    Eli Lilly

    U.S.A arrow
    World Vaccine Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Glycopyrronium Tosylate

    Therapeutic Area : Dermatology

    Study Phase : Approved FDF

    Sponsor : Journey Medical Corporation

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Journey Medical Corporation Enters into a Definitive Agreement with Dermira to Acquire QBREXZA®

    Details : QBREXZA is the only topical product to be approved by the U.S. Food and Drug Administration (FDA) for treatment of primary axillary hyperhidrosis in adult and pediatric populations (ages nine-years and older) and is self-administered by patients.

    Product Name : Qbrexza

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    January 04, 2021

    Lead Product(s) : Glycopyrronium Tosylate

    Therapeutic Area : Dermatology

    Highest Development Status : Approved FDF

    Sponsor : Journey Medical Corporation

    Deal Size : Undisclosed

    Deal Type : Acquisition

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth